|
Sex
| | |
|
Male
|
49
|
55.1
|
|
Female
|
40
|
44.9
|
|
Age
| | |
|
Median
|
62
| |
|
Range
|
36-80
| |
|
ECOG PS
| | |
|
0
|
66
|
74.2
|
|
1
|
23
|
25.8
|
|
Primary tumor
| | |
|
Colon
|
56
|
62.9
|
|
Rectum
|
33
|
37.1
|
|
Histological classification
| | |
|
Tubular adenocarcinoma (well-differentiated type)
|
27
|
30.3
|
|
Tubular adenocarcinoma (moderately-differentiated type)
|
50
|
56.2
|
|
Poorly-differentiated adenocarcinoma
|
9
|
10.1
|
|
Mucinous adenocarcinoma
|
3
|
3.4
|
|
Number of metastatic sites
| | |
|
1
|
37
|
41.6
|
|
2≤
|
52
|
58.4
|
|
UGT1A1*28/*6 polymorphism
| | |
|
Wild-type group
|
52
|
58.4
|
|
Heterozygous group
|
37
|
41.6
|
|
First-line treatment
| | |
|
Refractory (PD) / intolerable (adverse event) to oxaliplatin-based treatment
|
46/43
|
51.7/48.3
|
|
With/without bevacizumab
|
69/20
|
77.5/22.5
|
